S&P 500 Pushes for 9th Straight Day of Gains, Eli Lilly Says Weight-Loss Drug Reduces Diabetes Risk
The Rundown
00:00
Market Shifts: Weight-Loss Drug, Paramount Buyout, and Cybersecurity Gains
This chapter explores Eli Lilly's successful weight-loss drug and its implications for diabetes prevention, alongside the latest developments in Paramount's buyout saga. It also examines Palo Alto Networks' robust earnings and the rising significance of cybersecurity amid current corporate hurdles.
Transcript
Play full episode
